Medicine reference
Pramlintide
A source-linked medicine reference on Pramlintide, its documented context and safety boundaries. Sources checked 6 September 2026.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 March 2027.
Identity and scope
Pramlintide is a prescription amylin analogue used with insulin in selected diabetes care. It is not a general appetite-management product.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Documented context
The cited monograph describes diabetes use alongside insulin. It does not establish a standalone weight-loss or wellness indication.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Safety and a useful record
Severe hypoglycaemia risk and the interaction with insulin make supervised medicine use central. A change should be coordinated with the prescribing team.
Sources: MedlinePlus / American Society of Health-System Pharmacists
Record insulin regimen, glucose records, prescribed product and any low-glucose symptoms.
Published sources
- Pramlintide injection
MedlinePlus / American Society of Health-System Pharmacists. Current ASHP consumer monograph; accessed 6 September 2026.
Supports: Diabetes medicine identity, use and hypoglycaemia-risk context.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.